Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
19.6.2020 01:15:00 EEST | Business Wire | Press release
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.
Personalis will present “Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform“ in an industry-sponsored symposium, featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. Erin Newburn, MS, PhD, will present for Personalis.
Dr. Newburn will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, and oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status. In addition, Dr. Newburn will present a recent case study from a cohort of metastatic melanoma patients who were treated with an immune checkpoint blockade, where we integrated several different molecular features from the ImmunoID NeXT Platform™ to help better define the responder and non-responder patients.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts, including, for example, statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005949/en/
Contact information
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Braskem to Showcase Sustainable Packaging Solutions at interpack 202628.4.2026 11:00:00 EEST | Press release
Braskem (B3: BRKM3, BRKM5, and BRKM6, NYSE: BAK, LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer producer of biopolymers on an industrial scale, will be at interpack 2026 in hall 9, booth A32, presenting packaging solutions made from bio-based, recycled and traditional polyolefins, enabling circular plastics, end-to-end. At interpack, Braskem will highlight I’m green™ bio‑based polyethylene grades specifically engineered for food‑contact applications, as well as Medcol V7040, a new grade for Healthcare and Hygiene. These innovations mark the first time Braskem has offered sustainably sourced sugarcane‑derived plastics for these segments. In an environment where packaging decisions are increasingly evaluated on both sustainability ambitions and business impact, Braskem positions itself as a materials partner offering multiple, complementary pathways toward circularity and lower emissions. Rather than a one‑size‑fits‑all solu
Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America28.4.2026 10:00:00 EEST | Press release
Albion, a leading provider of telecom managed services and solutions, today announced that TELUS has selected Albion, in partnership with Tecnotree, to deliver a next-generation Value-Added Services (VAS) platform, with an initial deployment of a voicemail application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428959214/en/ Albion and Tecnotree Partner to Deliver Next-Generation VAS Platform for TELUS in North America Under the engagement, Albion will deliver the solution leveraging Tecnotree’s proven VAS and digital services platform, supporting TELUS’ objectives to modernize service capabilities; enhance the customer experience; and ensure scalable, future-ready service delivery. As part of the deployment, Albion will provide end-to-end managed services, including platform operations, service assurance, and ongoing lifecycle management, ensuring high availability and performance for TELUS customers across North Ame
Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026 ™28.4.2026 10:00:00 EEST | Press release
Today, Budweiser, the Official Beer Sponsor of the FIFA World Cup 2026™, unveiled its newest global football platform, “Let It Pour,” cracking open four years' worth of anticipation for the game’s biggest stage. Activating across more than forty countries, the global beer icon is supercharging celebrations with Bud FC fan events, The Bud Fan Store, and a new global film calling the world together to Let It Pour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428722336/en/ Budweiser Partners with Football Icons Erling Haaland and Jürgen Klopp to Unleash New “Let it Pour” Platform for FIFA World Cup 2026™ “For over four decades, Budweiser has been part of the celebrations that define the FIFA World Cup™, be it on the pitch, in bars, or wherever fans come together,” said Richard Oppy, Global President, Premium Company at AB InBev. “‘Let It Pour’ is our invitation to consumers to fully embrace those moments. Alongside Erling
Roquette Showcases Its Expanded Consumer Healthcare Capabilities at Vitafoods Europe 202628.4.2026 10:00:00 EEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will present its expanded portfolio at Vitafoods Europe 2026 which is taking place from May 5 to May 7 in Barcelona. Roquette’s offering is designed to help consumer healthcare brands stay future‑ready and accelerate consumer-centric innovations for everyday well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428405433/en/ Credits to Roquette As consumer expectations rise and shelf competition intensifies, dietary supplement and over-the-counter (OTC) brands, as well as contract development and manufacturing organizations (CDMOs), face growing pressure to deliver clean-label products that combine efficacy, strong sensory experiences, regulatory confidence, and speed to market. At Vitafoods Europe 2026, Roquette will demonstrate its role as a versatile partner, supporting customers from early concept to commercial launch a
LTM Launches BlueVerse™ Studio as a Hub for Enterprise Agentic AI Adoption28.4.2026 08:00:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of its BlueVerse Studio in Bengaluru, a hub designed to accelerate Enterprise Agentic AI adoption for clients and deliver measurable business outcomes. LTM continues to launch more studios globally to drive AI innovation and also has studios in London and Mumbai. As part of the company’s ongoing investment in bringing innovation closer to clients, the BlueVerse Studio was created to help clients scale AI solutions from experiments to practical applications while ensuring trust and control. It unites LTM’s strongest AI capabilities, including BlueVerse CraftStudio, physical AI showcases, and industry-centric AI offerings, within one ecosystem along with: Multiple BlueVerse-certified consulting and delivery professionals currently support enterprise-grade AI solutions. These certifications provide expertise in developing intelligent agents and managing unified AI platforms, ensuring secure
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom